IP Library Granted Patent US 11,224,207
Granted Patent B2
US 11,224,207 · App. 15/703,490 · Granted Jan 18, 2022

Non-human animals expressing pH-sensitive immunoglobulin sequences

Inventors: John McWhirter (Greenville, NC); Lynn Macdonald (Harrison, NY); Joel H. Martin (Putnam Valley, NY); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneran Pharmaceuticals, Inc.
A01K67/0275A01K67/0278C07K16/00C12N15/8509A01K2217/072A01K2217/075A01K2217/15A01K2227/105A01K2267/01C07K2317/10C07K2317/21C07K2317/92C07K2317/94C12N2800/204
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,224,207
App. No.
15/703,490
Granted
Jan 18, 2022
Kind
B2
Abstract

Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a histidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and/or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.

Claims (28)

1. A genetically modified rodent that makes antibody variable domains, each with a histidine encoded by a germline histidine codon, the rodent comprising, in its germline and at an endogenous immunoglobulin light chain locus, an unrearranged human immunoglobulin light chain variable gene sequence operably linked to an endogenous immunoglobulin light chain constant region nucleic acid sequence at the endogenous immunoglobulin light chain locus,

wherein the unrearranged human immunoglobulin variable gene sequence comprises no more than two unrearranged human immunoglobulin light chain variable (V L ) gene segments and one or more unrearranged human immunoglobulin light chain joining (J L ) gene segment,

wherein a complementarity determining region 3 (CDR3) encoding sequence of each of the no more than two unrearranged human V L gene segments comprises a substitution of a non-histidine codon with a histidine codon or an insertion of a histidine codon,

wherein two, three, four or more CDR3 codons of at least one of the no more than two unrearranged human V L gene segments comprises a substitution of a non-histidine codon with a histidine codon or an insertion of a histidine codon,

wherein each inserted or substituted histidine codon is at a position selected from the group consisting of 105, 106, 107, 108, 109, and 111 (according to IMGT numbering), and

wherein the rodent further comprises in vivo a diverse repertoire of antibodies, each of which is specific for an antigen of interest and comprises a human immunoglobulin light chain variable domain that (a) retains at least one histidine amino acid, which is in a CDR3 and is encoded by the substituted or inserted histidine codon and (b) is operably linked to an endogenous immunoglobulin light chain constant domain.

2. The genetically modified rodent of claim 1 , wherein the unrearranged human immunoglobulin V L and J L gene segments are unrearranged human immunoglobulin V K and J K gene segments.

3. The genetically modified rodent of claim 1 , wherein the rodent is a rat or a mouse.

4. A method for obtaining an antigen-binding protein, comprising harvesting a lymphocyte from the genetically modified rodent of claim 1 .

5. The method of claim 4 , wherein the unrearranged human immunoglobulin V L and J L gene segments are unrearranged human immunoglobulin V K and J K gene segments.

6. The method of claim 4 , wherein the rodent is a rat or a mouse.

7. The method of claim 4 , further comprising the step of producing a hybridoma from the harvested lymphocyte.

8. A hybridoma produced according to the method of claim 7 .

9. An immunoglobulin variable domain made by the hybridoma of claim 8 .

10. The method of claim 4 , further comprising

obtaining from the harvested lymphocyte, or a hybridoma produced therefrom, a nucleotide sequence that encodes the immunoglobulin light chain variable domain that retains at least one histidine amino add derived from the substituted or inserted histidine codon in the germline genome; and

expressing in a cell a nucleic add operably linked to a human light chain constant region gene,

wherein the nucleic acid operably linked to a human light chain constant region gene comprises a sequence identical to the nucleotide sequence that encodes the immunoglobulin light chain variable domain that retains at least one histidine amino acid derived from the substituted or inserted histidine codon in the germline genome.

11. A nucleic acid comprising a sequence identical to the nucleotide sequence of claim 10 , wherein the nucleic acid comprises a sequence identical to the nucleotide sequence that encodes the immunoglobulin light chain variable domain that retains at least one histidine amino acid derived from the substituted or inserted histidine codon in the germline genome.

12. A cell comprising the nucleic acid of claim 11 , wherein the nucleic acid comprises a sequence identical to the nucleotide sequence that encodes the immunoglobulin light chain variable domain that retains at least one histidine amino acid derived from the substituted or inserted histidine codon in the germline genome.

13. An immunoglobulin variable domain made by the cell of claim claim 12 .

14. An immunoglobulin variable domain made by the cell obtained by the method of claim 4 .

15. A method for making the genetically modified rodent of claim 1 , comprising:

modifying a rodent in its germline genome to comprise at an endogenous immunoglobulin light chain locus an unrearranged human immunoglobulin light chain variable gene sequence operably linked to an endogenous immunoglobulin light chain constant region nucleic acid sequence at the endogenous immunoglobulin light chain locus,

wherein the unrearranged human immunoglobulin variable gene sequence comprises no more than two unrearranged human immunoglobulin V L gene segments and one or more unrearranged human immunoglobulin J L gene segments, and

wherein a CDR3 encoding sequence of each of the no more than two unrearranged human immunoglobulin VL gene segments comprises a substitution of a histidine codon for a non-histidine codon or an insertion of a histidine codon.

16. The method of claim 15 , wherein the unrearranged human immunoglobulin V L and J L gene segments are unrearranged human immunoglobulin V K and J K gene segments.

17. The method of claim 15 , wherein the rodent is a rat or a mouse.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: MCWHIRTER, JOHN; MACDONALD, LYNN; MARTIN, JOEL H.; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 044078/0337 →
Continuity (6)
Continuation 13834129 · Mar 15, 2013
Provisional Application 61611950 · Mar 16, 2012
Provisional Application 61613352 · Mar 20, 2012
Provisional Application 61736930 · Dec 13, 2012
Provisional Application 61612126 · Mar 16, 2012
Related Publication 20170367308A1 · Dec 28, 2017